Characterization of the differential efficiacy of somatostatin receptor agonists in the inhibition of the growth of experimental gliomas and identification of the intracellular mechanisms involved

European journal of Clinical and Medical Oncology

Volumn 3, Issue 3, 2011, Pages 46-53

  Barbieri, Federica ^a   Florio, Tullio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Agonist; Glioma; Proliferation; Somatostatin receptor

Indexed keywords

CYTOSTATIC AGENT; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE PHOSPHATASE; SOMATOSTATIN RECEPTOR;

BRAIN CANCER; CANCER INHIBITION; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CYTOSTASIS; ENDOCRINE CELL; EPITHELIUM CELL; EXPERIMENTAL MODEL; GLIOBLASTOMA; GLIOMA; HUMAN; IN VITRO STUDY; INDIVIDUALIZATION; INTROSPECTION; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; REVIEW; TUMOR CELL; TUMOR GROWTH; UPREGULATION; VASCULAR LESION;

EID: 79960105189     PISSN: 17598958     EISSN: 17598966     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;203:157-198.
2. Moller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta. 2003;16161:1-84.
3. Hoyer D, Bell GI, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. 1995;163:86-88.
4. Alderton F, Fan TP, Schindler M, Humphrey PP. Rat somatostatin sst2(a) and sst2(b) receptor isoforms mediate opposite effects on cell proliferation. Br J Pharmacol. 1998;1258:1630-1633.
5. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology. 1994; 1356:2814-2817.
6. Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer. 2005;124:683-699.
7. Schonbrunn A. Selective agonism in somatostatin receptor signaling and regulation. Mol Cell Endocrinol. 2008;2861-2862:35-39.
8. Jacobs S, Schulz S. Intracellular trafficking of somatostatin receptors. Mol Cell Endocrinol. 2008;2861-2862:58-62.
9. Florio T, Yao H, Carey KD, Dillon TJ, Stork PJ. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol Endocrinol. 1999;131:24-37.
10. Florio T, Thellung S, Arena S, et al. Somatostatin receptor 1 (SSTR1)- mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J Physiol Paris. 2000;943-944:239-250.
11. Alderton F, Darroch P, Sambi B, et al. G-protein-coupled receptor stimulation of the p42/p44 mitogen-activated protein kinase pathway is attenuated by lipid phosphate phosphatases 1, 1a, and 2 in human embryonic kidney 293 cells. J Biol Chem. 2001;27616:13452-13460.
12. Pan MG, Florio T, Stork PJ. G protein activation of a hormone-stimulated phosphatase in human tumor cells. Science. 1992;2565060:1215-1217.
13. Florio T, Rim C, Hershberger RE, Loda M, Stork PJ. The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Mol Endocrinol. 1994;810:1289-1297.
14. Pages P, Benali N, Saint-Laurent N, et al. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J Biol Chem. 1999;27421:15186-15193.
15. Ferjoux G, Lopez F, Esteve JP, et al. Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol Biol Cell. 2003;149:3911-3928.
16. 3 thyroid cell proliferation. Mol Endocrinol. 2001;1510:1838-1852.
17. Florio T. Somatostatin/somatostatin receptor signalling: Phosphotyrosine phosphatases. Mol Cell Endocrinol. 2008;2861-2862:40-48.
18. Schweitzer P, Madamba S, Siggins GR. Arachidonic acid metabolites as mediators of somatostatin-induced increase of neuronal M-current. Nature. 1990;3466283:464-467.
19. Colucci R, Blandizzi C, Ghisu N, Florio T, Del Tacca M. Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation. Br J Pharmacol. 2008;1552:198-209.
20. Csaba Z, Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides. 2001;351:1-23.
21. Ferrante E, Pellegrini C, Bondioni S, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer. 2006;133:955-962.
22. Florio T, Morini M, Villa V, et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology. 2003;1444:1574-1584.
23. Balaban CD, Severs WB. Cytotoxic effects of somatostatin in the cerebellum. Ann N Y Acad Sci. 1992;656:802-810.
24. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy. 2001;47 Suppl 2:30-39.
25. Wulbrand U, Feldman M, Pfestroff A, et al. A novel somatostatin conjugate with a high affinity to all five somatostatin receptor subtypes. Cancer. 2002;944 Suppl:1293-1297.
26. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008;2861-2862:230-237.
27. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008;13:822-840.
28. Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W. Regulation and function of somatostatin receptors. J Neurochem. 2004;895:1057-1091.
29. Viollet C, Lepousez G, Loudes C, Videau C, Simon A, Epelbaum J. Somatostatinergic systems in brain: networks and functions. Mol Cell Endocrinol. 2008;2861-2862:75-87.
30. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;1712:1733-1742.
31. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;212:999-1017.
32. Reubi JC, Laissue JA. Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci. 1995;163:110-115.
33. Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol. 2007;1561:65-74.
34. Li M, Li W, Kim HJ, Yao Q, Chen C, Fisher WE. Characterization of somatostatin receptor expression in human pancreatic cancer using realtime RT-PCR. J Surg Res. 2004;1192:130-137.
35. Sagman U, Mullen JB, Kovacs K, Kerbel R, Ginsberg R, Reubi JC. Identification of somatostatin receptors in human small cell lung carcinoma. Cancer. 1990;6610:2129-2133.
36. Pisarek H, Stepien T, Kubiak R, Borkowska E, Pawlikowski M. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res. 2009;21:1.
37. Hofland LJ, Lamberts SW. Somatostatin receptor subtype expression in human tumors. Ann Oncol. 2001;12 Suppl 2:S31-36.
38. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1- sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001; 287:836-846.
39. Watt HL, Kharmate G, Kumar U. Biology of somatostatin in breast cancer. Mol Cell Endocrinol. 2008;2861-2862:251-261.
40. Massa A, Barbieri F, Aiello C, et al. The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation. J Biol Chem. 2004; 27928:29004-29012.
41. Arena S, Barbieri F, Thellung S, et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol. 2004;661-662:155-166.
42. Ioannou M, Papagelopoulos PJ, Papanastassiou I, Iakovidou I, Kottakis S, Demertzis N. Detection of somatostatin receptors in human osteosarcoma. World J Surg Oncol. 2008;6:99.
43. Janson ET, Stridsberg M, Gobl A, Westlin JE, Oberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res. 1998;5811:2375-2378.
44. Fjallskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B, Janson ET. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol. 2003;201:59-67.
45. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab. 2000;857:2564-2571.
46. Palmieri G, Montella L, Aiello C, et al. Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract. Amino Acids. 2007; 323:395-400.
47. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 1994; 5413:3455-3459.
48. Kulaksiz H, Eissele R, Rossler D, Schulz S, Hollt V, Cetin Y, Arnold R. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002; 501:52-60.
49. Florio T, Montella L, Corsaro A, et al. In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors. Anticancer Res. 2003;233B:2465-2471.
50. Florio T, Barbieri F, Spaziante R, et al. Efficacy of a dopaminesomatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multicenter study. Endocr Relat Cancer. 2008;152:583-596.
51. Florio T, Thellung S, Corsaro A, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GHsecreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf). 2003; 591:115-128.
52. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;244:389-427.
53. Watson JC, Balster DA, Gebhardt BM, et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer. 2001;852:266-272.
54. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. 2004;1021:61-85.
55. Woltering EA. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm. 2003;184:601-609.
56. Albini A, Florio T, Giunciuglio D, et al. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. Faseb J. 1999;136:647-655.
57. Aavik E, Luoto NM, Petrov L, Aavik S, Patel YC, Hayry P. Elimination of vascular fibrointimal hyperplasia by somatostatin receptor 1,4-selective agonist. Faseb J. 2002;167:724-726.
58. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem. 2000;27511:7862-7869.
59. Buscail L, Delesque N, Esteve JP, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A. 1994;916:2315-2319.
60. Florio T, Thellung S, Arena S, et al. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol. 1999;1414:396-408.
61. Reardon DB, Dent P, Wood SL, Kong T, Sturgill TW. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol Endocrinol. 1997;118:1062-1069.
62. Roskoski R, Jr. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun. 2005;3311:1-14.
63. Lopez F, Ferjoux G, Cordelier P, et al. Neuronal nitric oxide synthase: a substrate for SHP-1 involved in sst2 somatostatin receptor growth inhibitory signaling. Faseb J. 2001;1512:2300-2302.
64. Theodoropoulou M, Zhang J, Laupheimer S, et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2006;663:1576-1582.
65. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006;64:307-320.
66. Iuliano R, Trapasso F, Le Pera I, et al. An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res. 2003; 634:882-886.
67. 3 thyroid cell proliferation through the modulation of phosphotyrosine activity. Impairment of the somatostatinergic effects by stable expression of E1A viral oncogene. J Biol Chem. 1996;27111:6129-6136.
68. Hortala M, Ferjoux G, Estival A, et al. Inhibitory role of the somatostatin receptor SST2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform: implication of JAK2. J Biol Chem. 2003;27823:20574-20581.
69. Arena S, Pattarozzi A, Massa A, et al. An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase eta. Mol Endocrinol. 2007;211:229-246.
70. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;156:966-973.
71. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer. 2008;153:701-720.
72. Feindt J, Becker I, Blomer U, et al. Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J Neurochem. 1995;655:1997-2005.
73. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;1142:97-109.
74. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;2121:2683-2710.
75. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;6318:5821-5828.
76. Hide T, Takezaki T, Nakamura H, Kuratsu J, Kondo T. Brain tumor stem cells as research and treatment targets. Brain Tumor Pathol. 2008; 252:67-72.
77. Griffero F, Daga A, Marubbi D, et al. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem. 2009;28411:7138-7148.
78. Wen PY. New developments in targeted molecular therapies for glioblastoma. Expert Rev Anticancer Ther. 2009;91:7-10.
79. Dutour A, Kumar U, Panetta R, et al. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998;765:620-627.
80. Massa A, Barbieri F, Aiello C, et al. The phosphotyrosine phosphatase eta mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2. Ann N Y Acad Sci. 2004;1030:264-274.
81. Lamszus K, Meyerhof W, Westphal M. Somatostatin and somatostatin receptors in the diagnosis and treatment of gliomas. J Neurooncol. 1997; 353:353-364.
82. Mawrin C, Schulz S, Pauli SU, et al. Differential expression of sst1, sst2A, and sst3 somatostatin receptor proteins in low-grade and high-grade astrocytomas. J Neuropathol Exp Neurol. 2004;631:13-19.
83. Barbieri F, Pattarozzi A, Gatti M, et al. Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2. Endocrinology. 2008;1499:4736-4746.
84. Rohrer SP, Birzin ET, Mosley RT, et al. Rapid identification of subtypeselective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998;2825389:737-740.
85. Grobben B, De Deyn PP, Slegers H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 2002;3103:257-270.
86. Barbieri F, Pattarozzi A, Gatti M, et al. Differential Efficacy of Sstr1, 2 and 5 Agonists in the Inhibition of C6 Glioma Growth in Nude Mice. Am J Physiol Endocrinol Metab. 2009;297:E1078-E1088.
87. Grant M, Alturaihi H, Jaquet P, Collier B, Kumar U. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol. 2008;2210: 2278-2292. Epub 008 Jul 24.
88. Hubina E, Nanzer AM, Hanson MR, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol. 2006;1552:371-379.